The GlycoMark test is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes. The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.
The GlycoMark 1,5-anhydroglucitol biomarker was discovered to be linked to diabetes by a Japanese researcher in the 1980s. Subsequently, over 40 clinical trials of the marker have been completed around the world. The test has been used in Japan as a standard glycemic biomarker since the early 1990s.
GlycoMark, Inc. is a joint venture of Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan). GlycoMark, Inc. brings exceptional resources to the discovery and commercialization of innovative biomarkers for diabetes.
Nippon Kayaku, Co., Ltd., a major Japanese pharmaceutical and biochemical firm, makes the GlycoMark test. Toyota Tsusho Corporation imports the GlycoMark test from Japan and provides commercialization support through GlycoMark, Inc.